Amgen, Immatics Launch Up-to-$1B+ Cancer Immunotherapy Alliance – Genetic Engineering & Biotechnology News
Investopedia |
Amgen, Immatics Launch Up-to-$1B+ Cancer Immunotherapy Alliance
Genetic Engineering & Biotechnology News Amgen will partner with Immatics Biotechnologies to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, through a collaboration the companies said today could generate more than $1 billion for Immatics. Amgen (AMGN), Immatics Biotechnologics To Collaborate On Novel Bispecific Cancer Immunotherapies Development Amgen, Immatics In Cancer Drug Partnership (AMGN) Amgen Invests $30M In Immatics, Up To $1 Billion In Future Payments |
